Pharmaceuticals Company Announces Positive Results From PTSD Treatment Study

Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX), a company dedicated to developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders, and anti-viral barrier indications, has recently announced promising results from a Swine Model pilot study for Probudur™, its long-acting liposomal bupivacaine formulation. This formulation aims to provide both immediate and extended pain relief when injected at a wound site. $Virpax Pharmaceuticals (VRPX.US)$